UBS ASSET MANAGEMENT AMERICAS LLC - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 129 filers reported holding AIMMUNE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is 0.94 and the average weighting 0.8%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$1,341,621,000
+103.7%
38,944
-1.2%
0.00%
Q2 2020$658,475,000
+17.8%
39,406
+1.6%
0.00%
Q1 2020$559,150,000
-59.0%
38,776
-4.8%
0.00%
-100.0%
Q4 2019$1,362,899,000
+55.4%
40,720
-2.8%
0.00%0.0%
Q3 2019$877,113,000
+2.6%
41,887
+2.1%
0.00%0.0%
Q2 2019$854,536,000
+56.9%
41,044
+68.4%
0.00%
Q1 2019$544,714,000
+9.0%
24,372
+16.6%
0.00%
Q4 2018$499,928,000
-12.3%
20,9000.0%0.00%
Q3 2018$570,152,000
+1.5%
20,9000.0%0.00%
Q2 2018$562,001,000
-21.0%
20,900
-6.5%
0.00%
-100.0%
Q1 2018$711,306,000
+111.3%
22,347
+151.1%
0.00%
Q4 2017$336,598,000
-95.3%
8,900
-96.9%
0.00%
-100.0%
Q3 2017$7,214,460,000291,0230.01%
Other shareholders

There were no reported owners of AIMMUNE THERAPEUTICS INC in Q1 2019.

NameSharesValueWeighting ↓
View complete list of AIMMUNE THERAPEUTICS INC shareholders